Why Recursion Pharamaceuticals Topped the Market Today

Recursion Pharmaceuticals (NASDAQ: RXRX) was in the headlines on Monday, and for the right reason. One of the biotech company's investigational drugs did well in a clinical trial, and investors rewarded the company by trading its stock more than 2% higher on the news. Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which polyps develop within the body, was found to reduce the total polyp burden in most of the trial's 12 participants. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool